Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > NEWS: Kalytera to complete name, symbol change April 12

<< Previous

Bullboard Posts

Next >>

Comment by polygraph46on Apr 08, 2021 1:18am

249 Views

Post# 32955017

RE:RE:RE:NEWS: Kalytera to complete name, symbol change April 12

Mr. Enzolini:

That's a good post. But hey, once the Kaly name gets tossed on April 12th, you are saying

that all the Kaly press releases, which were so full of potential for the past three/four years get

tossed as well? Seriously? I don't agree. Those releases are very important part of the Kaly story,

the history to its present demise. They just can't be tossed into the largest of garbage bins......can

they ? pg

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property